SCHEMBL4352375

SCHEMBL4352375

CCCN(Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
ALDH1A1 P00352 2/20 0.49
ALDH2 P05091 1/20 0.49
ESR1 P03372 3/20 0.45
ESR2 Q92731 1/20 0.45
POLB P06746 1/20 0.45
APEX1 P27695 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
LMNA P02545 2/20 0.44
LTB4R2 Q9NPC1 1/20 0.44
ADRA2A P08913 2/20 0.44
ADORA3 P0DMS8 2/20 0.44
TACR2 P21452 2/20 0.44
SLC6A2 P23975 2/20 0.44
SLC6A4 P31645 2/20 0.44
SLC6A3 Q01959 2/20 0.44
TP53 P04637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
SHBG P04278 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL574486 0.85 LMNA (0.61) HDAC1HDAC6ALDH1A1LMNATP53
SCHEMBL5031990 0.82 HDAC1 (0.48) HDAC1HDAC6ALDH1A1POLBAPEX1
SCHEMBL375755 0.79 FNTA (0.59) HDAC1HDAC6ALDH1A1ESR1TDP1
SCHEMBL4489409 0.77 MLYCD (0.64) HDAC1HDAC6ALDH1A1ESR1ESR2
SCHEMBL9416625 0.77 HDAC1 (0.56) HDAC1HDAC6TDP1LTB4R2PKM
SCHEMBL9416644 0.76 ALDH1A1 (0.50) ALDH1A1ALDH2ESR1ESR2LMNA
SCHEMBL1206711 0.76 HRH3 (0.69) ALDH1A1ALDH2ESR1LMNAADRA2A
SCHEMBL14362172 0.76 DPP4 (0.54)
SCHEMBL5933504 0.76 ALDH1A1 (0.58) HDAC1HDAC6ALDH1A1ALDH2POLB
SCHEMBL11142759 0.76 LMNA (0.64) HDAC1HDAC6ALDH1A1ALDH2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 HDAC1 886/4885HDAC6 1591/4885ALDH1A1 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.